Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Litchi procyanidins are oligomeric and polymeric flavan-3-ols extracted from various parts of the litchi (*Litchi chinensis*) fruit, including the pericarp (peel), seed, and pulp. They are especially rich in A-type procyanidins. Litchi procyanidins possess notable **antioxidant** activity, demonstrated by their ability to scavenge free radicals and reduce oxidative stress. Mechanistically, they exhibit **anti-inflammatory**, **antidiabetic**, **anti-atherosclerotic**, and **anticancer** properties. Preclinical studies show that litchi procyanidins inhibit colon cancer cell proliferation and metastasis, largely by modulating gut microbiota and enhancing CD8+ T cell immune responses. They also have potential to inhibit xanthine oxidase, decrease serum uric acid, and provide other metabolic and microbiome-related benefits. Main oligomeric constituents include epicatechin, procyanidin B2, procyanidin C1, and A-type trimeric procyanidins[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on litchi procyanidins.